(MENAFN- GlobeNewsWire - Nasdaq) Dublin, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The "Gastrointestinal Collaboration and Licensing Deals 2016-2025" has been added to ResearchAndMarkets's offering.
Fully revised and updated, the report provides details of 398 gastrointestinal deals from 2016 to 2025.
Gastrointestinal Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the gastrointestinal deals entered into by the world's leading biopharma companies. The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters provide an orientation of gastrointestinal dealmaking and trends analysis. Chapter 1 introduces the report, while Chapter 2 delves into dealmaking trends. Chapter 3 outlines the financial terms by stage of development, and Chapter 4 reviews the top 25 active companies. Chapter 5 details deals since 2016 with available contract documents, and Chapter 6 lists deals by therapeutic target.
The report also includes numerous table and figures that illustrate the trends and activities in gastrointestinal deal making since 2016.
In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Gastrointestinal Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse gastrointestinal collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in gastrointestinal dealmaking
2.1. Introduction
2.2. Gastrointestinal partnering over the years
2.3. Gastrointestinal partnering by deal type
2.4. Gastrointestinal partnering by industry sector
2.5. Gastrointestinal partnering by stage of development
2.6. Gastrointestinal partnering by technology type
2.7. Gastrointestinal partnering by therapeutic indication
Chapter 3 - Financial deal terms for gastrointestinal partnering
3.1. Introduction
3.2. Disclosed financials terms for gastrointestinal partnering
3.3. Gastrointestinal partnering headline values
3.4. Gastrointestinal deal upfront payments
3.5. Gastrointestinal deal milestone payments
3.6. Gastrointestinal royalty rates
Chapter 4 - Leading gastrointestinal deals and dealmakers
4.1. Introduction
4.2. Most active in gastrointestinal partnering
4.3. List of most active dealmakers in gastrointestinal
4.4. Top gastrointestinal deals by value
Chapter 5 - Gastrointestinal contract document directory
5.1. Introduction
5.2. Gastrointestinal partnering deals where contract document available
Chapter 6 - Gastrointestinal dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by gastrointestinal therapeutic target
Companies Featured

• 4SC
• 9 Meters Biopharma
• Aayam Therapeutics
• Abbvie
• Ab E Discovery
• Aclipse Therapeutics
• AdaptivEndo
• AdaptVac
• Adiso Therapeutics
• ADL Bionatur Solutions
• Advanced Biological Laboratories
• Aerpio Pharmaceuticals
• Aevi Genomic Medicine
• AgomAb Therapeutics
• AIG Hospitals
• AI Medical Service
• Akebia Therapeutics
• Alba Therapeutics
• Alfasigma
• Alimentiv
• Alivio Therapeutics
• Allergan
• Allied Digestive Health
• Alma Bio Therapeutics
• Altos Group
• Alvit LCS Pharma
• Alvotech
• Ambry Genetics
• Amgen
• AnimalBiome
• Anokion
• Antibe Therapeutics
• Apogee Biotechnology
• Applied BioMath
• Arcadia Consumer Healthcare
• Ardelyx
• Arena Pharmaceuticals
• Ariel Precision Medicine
• Aries Pharmaceuticals
• Aristea Therapeutics
• Artizan Biosciences
• Asahi Kasei
• AscentX Medical
• Aslan Pharma
• Assembly Biosciences
• Associazione Poic e Dintorni APS
• Astellas Pharma
• AstraZeneca
• Asymchem Laboratories
• Athos Therapeutics

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN19112025004107003653ID1110368165